Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine
The new 10-year contract will focus on strengthening the partnership for continued transformative innovation for patients
Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD)
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Open a printable version of this pageEmail the URL of this page to a friend
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
Currently, Sharma is a part of the Philippines Country Leadership Team as Business Unit Head Respiratory & Immunology
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
Subscribe To Our Newsletter & Stay Updated
